ClearPoint Neuro (CLPT) Capital Expenditures Growth (3y) (2014 - 2026)
ClearPoint Neuro (CLPT) Capital Expenditures Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.27 Bn | 175.98 Bn | 6.27 Bn | 1.64% |
| 2 | Stryker | 128.81 Bn | 125.93 Bn | 3.81 Bn | 8.49% |
| 3 | Medtronic | 108.63 Bn | 99.41 Bn | 6.41 Bn | 8.89% |
| 4 | Boston Scientific | 68.42 Bn | 66.96 Bn | 3.61 Bn | 16.83% |
| 5 | Edwards Lifesciences | 48.51 Bn | 44.84 Bn | 1.29 Bn | 1.81% |
| 6 | Dexcom | 28.39 Bn | 27.27 Bn | 750.30 Mn | 0.84% |
| 7 | GE HealthCare Technologies | 28.31 Bn | 26.03 Bn | 1.98 Bn | 7.57% |
| 8 | Smith & Nephew | 26.93 Bn | 26.35 Bn | - | - |
| 9 | Koninklijke Philips | 25.47 Bn | 22.35 Bn | 2.07 Bn | 2.15% |
| 10 | ClearPoint Neuro | 428.78 Mn | 393.18 Mn | 7.76 Mn | 67.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 67.20% |
| Dec 31, 2025 | 7.91% |
| Sep 30, 2025 | 42.34% |
| Jun 30, 2025 | 6.19% |
| Mar 31, 2025 | 38.42% |
| Dec 31, 2024 | 90.57% |
| Sep 30, 2024 | -54.21% |
| Dec 31, 2022 | 491.80% |
| Dec 31, 2021 | 256.46% |
| Sep 30, 2021 | 123.78% |
| Jun 30, 2021 | -46.35% |
| Mar 31, 2021 | 24.66% |
| Sep 30, 2018 | -44.33% |
| Jun 30, 2018 | 246.44% |
| Mar 31, 2018 | 45.99% |
| Mar 31, 2016 | 113.44% |
| Sep 30, 2015 | 97.47% |
| Jun 30, 2015 | -79.02% |
| Mar 31, 2015 | 13.64% |
| Dec 31, 2014 | 56.98% |